Methods of altering bone growth by administration of sost or wise antagonist or agonist
The present invention provides a method of promoting local bone growth by administering a therapeutic amount of a Sost antagonist to a mammalian patient in need thereof. Preferably, the Sost antagonist is an antibody or FAB fragment selectively recognizing any one of SEQ ID NOS: 1-23. The Sost antagonist may be coadministered together or sequentially with a matrix conducive to anchoring new bone growth. Orthopedic and Periodontal devices comprising an implantable portion adapted to be permanently implanted within a mammalian body and bearing an external coating of a Sost antagonist are also disclosed, as it a method of increasing bone density by administering to a mammalian patient a therapeutic amount of a Sost antagonist together with an antiresorptive drug.
1. A method of increasing bone density in a mammalian patient in need thereof, comprising the steps of:
systemically administering to a said mammalian patient a therapeutic comprising an effective amount of a Sclerostin antagonist sequentially with an antiresorptive drug, said Sclerostin antagonist comprising an antibody or FAB fragment specifically binding a peptide selected from the group consisting of SEQ ID NOS:2-13, 22 and 23, wherein
the antibody interferes with Sclerositn's ability to bind to LRP, thereby systemically increasing bone density.
2. The method according to claim 1 , wherein said patient is a human.
3. The method according to claim 2 , wherein said patient has low bone density.
4. The method according to claim 3 , wherein said antibody or FAB fragment is a monoclonal antibody or FAB fragment.
5. The method according to claim 4 , wherein said monoclonal antibody or FAB fragment is humanized.
6. The method according to claim 3 , wherein said antiresorptive is a bisphosphonate, calcitonin, Vitamin D or SERM.
7. The method according to claim 3 , wherein said antiresorptive is fosamax, actonel, Miacalcic or Evista.
8. The method according to claim 3 , wherein said Sclerostin antagonist is administered to said patient prior to administering said antiresorptive.
9. The method according to claim 3 , wherein said antiresorptive is administered to said patient prior to administering said Sclerostin antagonist.
10. The method according to claim 3 , wherein said patient has previously been treated with an antiresorptive drug.
11. The method according to claim 3 , wherein said patient has not previously been treated with an antiresorptive drug.